» Articles » PMID: 38987843

Development of a Prognostic Risk Model of Uveal Melanoma Based on N7-methylguanosine-related Regulators

Overview
Journal Hereditas
Specialty Genetics
Date 2024 Jul 10
PMID 38987843
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Uveal melanoma (UVM) stands as the predominant type of primary intraocular malignancy among adults. The clinical significance of N7-methylguanosine (m7G), a prevalent RNA modifications, in UVM remains unclear.

Methods: Primary information from 80 UVM patients were analyzed as the training set, incorporating clinical information, mutation annotations and mRNA expression obtained from The Cancer Genome Atlas (TCGA) website. The validation set was carried out using Gene Expression Omnibus (GEO) database GSE22138 and GSE84976. Kaplan-Meier and Cox regression of univariate analyses were subjected to identify m7G-related regulators as prognostic genes.

Result: A prognostic risk model comprising EIF4E2, NUDT16, SNUPN and WDR4 was established through Cox regression of LASSO. Evaluation of the model's predictability for UVM patients' prognosis by Receiver Operating Characteristic (ROC) curves in the training set, demonstrated excellent performance Area Under the Curve (AUC) > 0.75. The high-risk prognosis within the TCGA cohort exhibit a notable worse outcome. Additionally, an independent correlation between the risk score and overall survival (OS) among UVM patients were identified. External validation of this model was carried out using the validation sets (GSE22138 and GSE84976). Immune-related analysis revealed that patients with high score of m7G-related risk model exhibited elevated level of immune infiltration and immune checkpoint gene expression.

Conclusion: We have developed a risk prediction model based on four m7G-related regulators, facilitating effective estimate UVM patients' survival by clinicians. Our findings shed novel light on essential role of m7G-related regulators in UVM and suggest potential novel targets for the diagnosis, prognosis and therapy of UVM.

Citing Articles

Correction: Development of a prognostic risk model of uveal melanoma based on N7-methylguanosine-related regulators.

Wu P, Zhang Q, Zhong P, Chai L, Luo Q, Jia C Hereditas. 2024; 161(1):23.

PMID: 39049112 PMC: 11267662. DOI: 10.1186/s41065-024-00326-y.

References
1.
McLaughlin C, Wu X, Jemal A, Martin H, Roche L, Chen V . Incidence of noncutaneous melanomas in the U.S. Cancer. 2005; 103(5):1000-7. DOI: 10.1002/cncr.20866. View

2.
Peng S, Guo P, Lin X, An Y, Sze K, Lau M . CAG RNAs induce DNA damage and apoptosis by silencing expression in polyglutamine degeneration. Proc Natl Acad Sci U S A. 2021; 118(19). PMC: 8126783. DOI: 10.1073/pnas.2022940118. View

3.
Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

4.
Weber J, DAngelo S, Minor D, Hodi F, Gutzmer R, Neyns B . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16(4):375-84. DOI: 10.1016/S1470-2045(15)70076-8. View

5.
Rozeman E, Prevoo W, Meier M, Sikorska K, Van T, van de Wiel B . Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). Melanoma Res. 2020; 30(3):252-260. DOI: 10.1097/CMR.0000000000000653. View